Acute lymphocytic leukemia in a child with congenital xanthine oxidase deficiency: implications for therapy.
Xanthine oxidase deficiency was identified in a 16-year-old girl with acute lymphocytic leukemia (ALL). Despite the enzyme deficiency, the patient tolerated high doses of 6-mercaptopurine (6-MP), a drug which is normally inactivated by the action of xanthine oxidase. This rate clinical situation may be analogous in the practice to that of the patient receiving 6-MP who is also given allopurinol, which inhibits xanthine oxidase activity. The implications of these observations on the determination of appropriate drug dosages for patients receiving these two agents are discussed.
D000293:Adolescent; D000493:Allopurinol / Q000627:therapeutic use; D001215:Asparaginase / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007945:Leukemia, Lymphoid / Q000150:complications* / Q000188:drug therapy; D008727:Methotrexate / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D013868:Thioinosine / Q000627:therapeutic use; D014527:Uric Acid / Q000652:urine; D014750:Vincristine / Q000627:therapeutic use; D014969:Xanthine Oxidase / Q000172:deficiency*
D014527:Uric Acid; D013868:Thioinosine; D014750:Vincristine; D000493:Allopurinol; D014969:Xanthine Oxidase; D001215:Asparaginase; D011241:Prednisone; D008727:Methotrexate